Helixor M

Helixor M is an injectable solution that contains a liquid extract of Viscum album subsp. album var. Malus domestica (1:20), prepared with water as the extraction solvent. Classified as a herbal medicinal product, it is administered subcutaneously for use in oncology care. The product is marketed in the European Union and is intended to be used under the supervision of a healthcare professional as part of a cancer treatment plan.

Helixor M is used as an adjunct in oncology settings, where it is administered alongside conventional cancer therapies to support the immune system and to provide supportive care.

- Adjunct therapy for solid tumors such as breast, lung, and colorectal cancer. - Supportive care to improve quality of life during chemotherapy or radiotherapy. - Immunomodulatory support in patients with hematologic malignancies. - Part of integrative oncology protocols aimed at reducing treatment‑related fatigue. - Investigational use in clinical studies evaluating tumor‑associated immune response.

Side‑effect reporting for Helixor M reflects its herbal nature and subcutaneous administration, with most reactions being mild, generally self‑limiting, and reversible.

Common: - Local redness, swelling, or mild pain at the injection site. - Low‑grade fever or transient chills. - Mild fatigue or headache.

Serious: - Severe allergic reaction (anaphylaxis) with breathing difficulty. - Persistent high fever (>38.5 °C) lasting more than 24 hours. - Unexplained bleeding, bruising, or sudden drop in blood pressure.

When prescribing Helixor M, clinicians should evaluate patient history and monitor for specific conditions that may increase the risk of adverse events or reduce therapeutic benefit.

- Avoid use in patients with known hypersensitivity to Viscum album extracts. - Exercise caution in individuals with autoimmune disorders or immunosuppression. - Monitor blood counts regularly during therapy. - Assess liver and kidney function before initiation and periodically thereafter. - Discuss potential effects with pregnant or breastfeeding women; safety data are limited. - Consider dose adjustments in elderly patients with comorbidities.

Helixor M may interact with other medications or biologic agents; awareness of these possibilities helps prevent reduced efficacy or heightened toxicity.

Avoid: - Concurrent use with immunosuppressive chemotherapy agents that may blunt the intended immunomodulatory effect. - Combination with other herbal preparations containing mistletoe extracts, which could increase toxicity.

Use with caution: - Anticoagulants or antiplatelet drugs, due to potential for increased bleeding risk. - Cytokine therapies (e.g., interferon) that may amplify immune activation. - Vaccinations, as immune modulation could affect vaccine response. - Hormonal therapies, pending clinical judgment.